Sorafenib

Liver Cancer

There are multiple clinical trials underway for individuals with liver cancer. For a more comprehensive list of Nexavar^® (sorafenib) clinical trials, please visit clinicaltrials.gov or call 866-639-2827.

Phase 3 Study of Sorafenib in Adjuvant Setting – STORM

Enrollment complete

Study Design: Randomized, double-blind, placebo-controlled study

Patients: Patients with HCC treatment following surgery or local treatment

Purpose: To compare the efficacy of sorafenib as an adjuvant treatment by assessing recurrence free survival, as well as differences in time to recurrence and overall survival

Location: North America, South America, Europe, and the Asia-Pacific region

Phase 3 Study of Sorafenib in Combination with Tarceva® (erlotinib) – SEARCH

Enrollment Complete

Study Design: Randomized, double-blind, placebo-controlled trial

Patients: Patients with unresectable, advanced or metastatic Child-Pugh A measurable liver cancer and who have had prior local therapy

Purpose: To determine the effectiveness of sorafenib plus Erlotinib when compared to sorafenib alone by assessing the difference in overall survival (OS), as well as to evaluate other measures of efficacy and safety

Location: Multiple centers throughout North America, Europe and the Asia-Pacific region